Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1847669 | 1.00 | EPHX2 (0.52) | EPHX2TSHRALDH1A1NPSR1POLB | |
| SCHEMBL1847665 | 1.00 | EPHX2 (0.52) | EPHX2TSHRALDH1A1NPSR1POLB | |
| SCHEMBL328950 | 1.00 | EPHX2 (0.52) | EPHX2TSHRALDH1A1NPSR1POLB | |
| SCHEMBL23815408 | 1.00 | EPHX2 (0.52) | EPHX2TSHRALDH1A1NPSR1POLB | |
| SCHEMBL1398388 | 0.83 | EPHX2 (0.52) | EPHX2TSHRALDH1A1NPSR1POLB | |
| SCHEMBL2719341 | 0.82 | EPHX2 (0.50) | EPHX2TSHRALDH1A1NPSR1POLB | |
| SCHEMBL6495033 | 0.82 | EPHX2 (0.50) | EPHX2TSHRALDH1A1NPSR1POLB | |
| SCHEMBL25041744 | 0.82 | EPHX2 (0.50) | EPHX2TSHRALDH1A1NPSR1POLB | |
| SCHEMBL19557168 | 0.79 | HSD11B1 (0.48) | EPHX2ALDH1A1HSD11B1L3MBTL1KDM4E | |
| SCHEMBL19557166 | 0.79 | HSD11B1 (0.48) | EPHX2ALDH1A1HSD11B1L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110159019-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-30 | — | — | US | disclosed |
| EP-2325175-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2011-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110159019-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | PRKCZ, DCLK1, AAK1 | EPHX2 2166/4885TSHR 4809/4885ALDH1A1 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.